Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium

被引:6
|
作者
Krzywdzinska, Agnieszka [1 ]
Pula, Bartosz [2 ]
Czyz, Anna [3 ]
Krzymieniewska, Beata [1 ]
Kiernicka-Parulska, Jolanta [4 ]
Mierzwa, Anna [4 ]
Szymczak, Donata [5 ]
Milanowska, Aneta [5 ]
Kiraga, Aleksandra [5 ]
Kwiecien, Iwona [6 ]
Zaleska, Joanna [7 ]
Jamroziak, Krzysztof [8 ]
机构
[1] Inst Hematol & Transfus Med, Lab Immunophenotyping, PL-02776 Warsaw, Poland
[2] Inst Hematol & Transfus Med, Dept Hematol, PL-02776 Warsaw, Poland
[3] Wroclaw Med Univ, Dept Hematol & Bone Marrow Transplantat, PL-50367 Wroclaw, Poland
[4] Univ Hosp Lords Transfigurat, Dept Haematol & Bone Marrow Transplantat, Flow Cytometry Lab, Haematol Clin Lab, PL-60101 Poznan, Poland
[5] Univ Hosp Wroclaw, Dept & Clin Haematol Blood Neoplasms & Bone Marro, Flow Cytometry & Cytomorphol Lab, PL-50367 Wroclaw, Poland
[6] Mil Inst Med, Dept Internal Med & Hematol, Lab Hematol & Flow Cytometry, PL-04141 Warsaw, Poland
[7] Med Univ Lublin, Dept Expt Hematooncol, PL-20059 Lublin, Poland
[8] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, PL-02097 Warsaw, Poland
关键词
multiple myeloma; minimal residual disease; flow cytometry; CONSENSUS GUIDELINES; DARATUMUMAB THERAPY; SURVIVAL OUTCOMES; MRD DETECTION; PLASMA-CELLS; SINGLE-TUBE; STANDARDIZATION; CD38;
D O I
10.3390/diagnostics11101872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Minimal residual disease (MRD) status is now considered as one of the most relevant prognostic factors in multiple myeloma (MM) while MRD negativity became an important endpoint in clinical trials. Here, we report the results of the first study evaluating the reproducibility of high-sensitivity flow cytometry MM MRD assessment in four laboratories in Poland. EuroFlow protocols for instrument setting standardization and sample preparation in MM MRD assessment were implemented in each laboratory. In the inter-laboratory reproducibility study, 12 bone marrow samples from MM patients were distributed and processed in participant laboratories. In the inter-operator concordance study, 13 raw data files from MM MRD measurements were analyzed by five independent operators. The inter-laboratory study showed high 95% overall concordance of results among laboratories. In the inter-operator study, 89% of MRD results reported were concordant, and the highest immunophenotype interpretation differences with regard to expression of CD27, CD45, CD81 were noticed. We confirmed the applicability and feasibility of the EuroFlow protocol as a highly sensitive method of MRD evaluation in MM. Results of our inter-center comparison study demonstrate that the standardization of MM MRD assessment protocols is highly desirable to improve quality and comparability of results within and between different clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Drug resistance and minimal residual disease in multiple myeloma
    Gozzetti, Alessandro
    Ciofini, Sara
    Sicuranza, Anna
    Pacelli, Paola
    Raspadori, Donatella
    Cencini, Emanuele
    Tocci, Dania
    Bocchia, Monica
    CANCER DRUG RESISTANCE, 2022, 5 (01) : 171 - 183
  • [42] Recommendations for quantitation of minimal residual disease in multiple myeloma
    Rasmussen, T
    Johnsen, HE
    BONE MARROW TRANSPLANTATION, 2002, 29 : S128 - S128
  • [43] Advances in minimal residual disease monitoring in multiple myeloma
    Wijnands, Charissa
    Noori, Somayya
    van de Donk, Niels W. C. J.
    VanDuijn, Martijn M.
    Jacobs, Joannes F. M.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2023, 60 (07) : 518 - 534
  • [44] Minimal residual disease in multiple myeloma: current status
    Hong Ding
    Juan Xu
    Zhimei Lin
    Jingcao Huang
    Fangfang Wang
    Yan Yang
    Yushan Cui
    Hongmei Luo
    Yuhan Gao
    Xinyu Zhai
    Weicui Pang
    Li Zhang
    Yuhuan Zheng
    Biomarker Research, 9
  • [45] Molecular detection of minimal residual disease in multiple myeloma
    Bai, Yinlei
    Orfao, Alberto
    Sang Chim, Chor
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 11 - 26
  • [46] RESPONSE ASSESSMENT IN MULTIPLE MYELOMA: CLINICAL SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING
    Paiva, Bruno
    Vidriales, Maria-Belen
    Montalban, Maria-Angeles
    Blade, Joan
    Lahuerta, Juan-Jose
    Orfao, Alberto
    San Miguel, Jesus F.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2011, 80B (06) : 390 - 390
  • [47] Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
    Jamet, Bastien
    Zamagni, Elena
    Nanni, Cristina
    Bailly, Clement
    Carlier, Thomas
    Touzeau, Cyrille
    Michaud, Anne-Victoire
    Moreau, Philippe
    Bodet-Milin, Caroline
    Kraeber-Bodere, Francoise
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 14
  • [48] New criteria for response assessment: role of minimal residual disease in multiple myeloma
    Paiva, Bruno
    van Dongen, Jacques J. M.
    Orfao, Alberto
    BLOOD, 2015, 125 (20) : 3059 - 3068
  • [49] Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma
    Correia, Nuno
    Dowling, Emma
    Popat, Rakesh
    Rabin, Neil
    Kyriakou, Chara
    Sive, Jonathan
    Yong, Kwee
    Wechalekar, Ashutosh
    BRITISH JOURNAL OF HAEMATOLOGY, 2023,
  • [50] The current status of minimal residual disease assessment in myeloma
    S K Kumar
    S V Rajkumar
    Leukemia, 2014, 28 : 239 - 240